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Objectives.- Secreted frizzled-related protein and sclerostin, encoded by FRZB and SOST 
genes, respectively, are extracellular Wnt inhibitors that tend to decrease bone formation. The 
purpose of this study was to explore the association of sets of polymorphisms capturing 
common variations of these genes with bone mineral density (BMD). 
Methods.- Twelve polymorphic loci of the FRZB gene and 7 of the SOST gene were 
genotyped in postmenopausal women from two Spanish regions (Cantabria, n=1043, and  
Valencia, n=342). The polymorphisms included tagging SNPs and SNPs with possible 
functional consequences assessed in silico. 
Results.-The rs4666865 polymorphism of the FRZB gene was associated with spine BMD in 
the Cantabria cohort in the single-locus (p=0.008) and the haplotypic analysis. However, the 
results were not replicated in the Valencia cohort. Several polymorphisms at the 5´region of 
the SOST gene, and particularly rs851056, were associated with BMD in women from both 
cohorts (p=0.002 in Cantabria and 0.005 in Valencia). When the results of both cohorts were 
combined, the mean BMD difference across rs851056 genotypes was 47 mg/cm2  or 0.31 
standard deviations (p<0.001). No differences in FRZB and SOST expression was detected 
across genotypes. 
Conclusions.- Polymorphisms in the 5’ region of SOST gene are associated with BMD in 
postmenopausal women, and consequently contribute to explain in part the hereditary 
influence on bone mass. 
 
 




The Wnt pathway has emerged as an important player in skeletal homeostasis. Wnt ligands  
promote the differentiation of mesenchymal precursors towards the osteoblastic lineage and  
have a positive effect on bone formation. On the other hand, they decrease the expression of 
RANKL by osteoblastic cells, which in turn inhibits osteoclast differentiation and bone 
resorption 1-4. Wnt receptors are membrane molecular complexes including LRP5/6 and a 
frizzled protein. A number of  extracellular Wnt inhibitors have been identified. Dickkopf 1 is a 
Wnt inhibitor, encoded by the DKK1 gene, which appears to play an important role in multiple 
myeloma and other skeletal tumours 5. Secreted frizzled-related protein 3 (SFRP3), the 
product of the FRZB gene, is related to membrane frizzled and binds Wnt ligands, thus 
preventing their binding to membrane receptors 6. Sclerostin, the product of the SOST gene, 
appears to interact with LRP5/6, making it unable to bind Wnt’s.  It has been suggested that  
polymorphisms of the genes encoding SFRP3 and sclerostin influence bone mass and the risk 
of skeletal diseases such as osteoarthritis and osteoporosis 7;8. Contradictory results were 
initially reported  regarding their influence on bone mass 9;10, and no evidence for association 
between polymorphisms of these genes and bone mineral density (BMD) was reported in two 
genome-wide association studies (GWAS) 11;12. However, some investigators later reported an  
association of  SOST alleles and BMD  13-15.  Three  markers located 23-57 kb downstream to 
the  SOST gene were also recently found as genome-wide significant quantitative trait loci in 
an extended GWAS in Iceland population 16. Differences in study subjects  and the markers 
selected may explain these contradictory results.  In fact, mixed populations, including men 
and women, pre and postmenopausal, or individuals with extreme BMD values were included 
in previous studies. Therefore, the aim of this study was to try to clarify the possible 
association of allelic variants of the FRZB and SOST genes with BMD in postmenopausal 




MATERIALS AND METHODS 
Subjects.- We studied 1043 postmenopausal women over 50 years of age (mean 66±8) living 
in Cantabria, a region in Northern Spain. They included volunteers recruited by 
advertisements and women sent to our clinic because of osteoporosis concerns.  Women with 
present or past diseases or treatments known to affect bone metabolism, or with non-Spanish 
ancestors (parents and grandparents) were excluded. BMD at the lumbar spine and femoral 
neck was measured by DXA using a Hologic QDR 4500 densitometer. Participants gave 
informed consent and the study was approved by the Clinical Research Ethical Committee of 
the Hospital U.M. Valdecilla. 
Positive results were replicated in a cohort of women attending a menopause clinic in 
Valencia, a region in Eastern Spain. After applying similar exclusion criteria, the cohort 
included 342 Caucasian postmenopausal women (more than 6 months since the last 
menstruation) aged 41-69 years (mean 52).  BMD was measured by DXA using either a DPX 
(GE Lunar Corporation, Madison, WI, USA) or a Norland XR-36 (Norland Medical Systems 
Inc; Fort Atkinson, WI, USA). The results from different densitometers were standardized as 
proposed by Lu and Hui 17;18.  
Genotyping.-  The Hapmap database was explored to identify SNPs of the FRZB and SOST 
regions in the Caucasian population. Then, tag-SNPs were selected using the algorithms 
available in Haploview with  the “aggressive tagging” option 19. Minor allele frequency (MAF) 
of 0.05 and r2 0.8 were used as criteria. In addition, we included two SNPs (rs7775 and 
rs1230395 in FRZB and SOST genes, respectively) with potential functional consequences, 
as assessed by PUPASUITE, a web tool that explores a variety of databases (coding SNPs, 
SNPs disrupting potential transcription factors binding sites, intron/exon boundaries) 20;21. DNA 
was isolated from peripheral blood by using column-based commercial methods and 
quantified with the Qubit procedure (Invitrogen, Carlsbad, CA, USA).   Then alleles at each 
locus were analyzed on a mass-array Sequenom platform at the Centro Nacional de 
Genotipado (Santiago de Compostela, Spain). Polymorphisms associated with BMD in the 
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Cantabria cohort were analyzed in Valencia cohort by using similar procedures for genotyping 
at Unidad Central de Investigación (Facultad de Medicina, Valencia, Spain). 
Gene expression.- Trabecular bone samples were obtained from the central part of the 
femoral heads of 27 patients undergoing hip replacement because of osteoarthritis, as 
previously reported 22. RNA was isolated with Trizol (Invitrogen), and further purified by using 
a column adsorption procedure (Qiagen, Hilden, Germany). Gene expression was analyzed 
by reverse transcription (RT) real-time polymerase chain reaction (PCR). Aliquots of RNA 
(250 ng) were reverse-transcribed with the Superscript III kit (Invitrogen). After RT, a  real-time 
PCR was done in an ABI7300 apparatus (Applied Biosystems, Foster City, CA), using specific 
primers and FAM-labelled probes for FRZB and SOST  (Taqman gene expression assays, 
Applied Biosystems). The results were then normalized to the expression of  the 
housekeeping gene TATA box protein (TBP) as 2-ΔCt, where ΔCt is the difference between 
either the  FRZB or SOST threshold cycle and TBP threshold cycle  23.    
Statistical analysis.- Haplotypic blocks were estimated by the method of Gabriel, implemented 
in Haploview 19. The departure from Hardy-Weinberg equilibrium (HWE) was tested with Plink 
software 24. The association of alleles with BMD was studied at the single-locus level, 
assuming codominant and recessive models, with Plink. The significance threshold after 
multiple test correction for each gene was estimated by considering the effective number of 
independent marker loci, as proposed by Li and Ji, using the single nucleotide spectral 
decomposition software (SNPSpD), developed by Nyholt 25. Haplotypic analyses were 
performed using the sliding window procedure including 3 consecutive SNPs. The presence of 
population stratification was explored with STRUCTURE software, running several datasets of 
5-68 markers 26. Results from different cohorts were combined with MIX software 27.Gene 
expression data, normalized by housekeeping gene expression, were log-transformed and 
compared by t-test.  Association between SNP genotypes and gene expression was also 
explored in silico comparing expression data in immortalized B-lymphocytes, using a database 
from the Sanger Institute GENEVAR project  28  and HapMap project, explored with 
WGAViever software 29. The study power to detect an a polymorphism explaining at least 
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1.5% variance of BMD under an additive model was more than 96% in the discovery cohort 
and more than 60% in the replication cohort (estimates obtained with QUANTO v1.2.3 
(available at available at http://hydra.usc.edu/gxe/). Uncorrected nominal p-values are shown, 





The polymorphisms studied are shown in table 1. Allelic frequencies were similar to those 
reported in the Hapmap database for the Caucasian population. There was no evidence for 
departure from HWE; some SNPs were associated with p-values in the 0.03-0.05 range, well 
above the multiple test significance threshold (see below). The characteristics of women 
included in the study are shown in table 2. 
FRZB 
Lumbar spine.-The rs4666865 polymorphism of the FRZB gene was associated with lumbar 
spine BMD (p=0.008; figure 1), but it did not reach the significance threshold after multiple test 
adjustment, estimated as 0.0051.  The average spine BMD in women with different genotypes 
was: GG, 0.850±0.156; GC, 0.861±0.140; CC, 0.884±0.149 g/cm2. Similar results were 
obtained including age and weight as covariates (not shown). In the multimarker analysis, 
haplotypes including this SNP and two neighbour downstream polymorphisms (rs7775 and 
rs6710705) showed the most significant association with BMD. Among the individual 
haplotypes, the frequent ACC haplotype showed the strongest association and explained 
0.9% of the overall variance in BMD (table 3). Spine BMD was 0.853±0.009, 0.867±0.145, and 
0.900±0.141 g/cm2, in women with 0, 1 and 2 copies of the ACC haplotype, respectively 
(p=0.002). In the haplotype conditional analysis, rs4666865 was independently associated 
with BMD (p=0.004), but rs7775 and rs6710705 were not (p=0.13 and 0.28, respectively). 
Femoral neck.- In the single locus analysis, rs4666865 showed a marginally significant 
association with femoral neck BMD. Average values were 0.678±0.120, 0.681±0.109 and 
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0.697±0.121 g/cm2 in women with GG, GC and CC genotypes, respectively (nominal p-
value=0.048). Several haplotypes including the rs4666865 locus were also associated with 
femoral neck BMD. As with spine BMD, the most significant one included rs4666865, rs7775 
and rs6710705 polymorphisms. Femoral neck BMD was 0.677±0.115, 0.683±0.110, and 
0.714±0.0.125 g/cm2, in women with 0, 1 and 2 copies of the ACC haplotype, respectively 
(p=0.0017) (table 3).  
When the association of haplotypic blocks (defined according to the Gabriel method, see 
figure 1) with BMD was studied, similar but slightly less significant results were found (lowest 
p-values were 0.004 and 0.005, for the association of block 2 haplotypes with spine and 
femoral BMD, respectively). 
SOST 
Lumbar spine.- There was an association between several linked polymorphisms in the 5’ 
region of the SOST gene and spine BMD, best fitting a recessive genetic model (figure 2). 
Thus, women homozygotes for the G minor allele at rs851056  had significantly lower BMD 
than women with other genotypes (p=0.0022), in the crude analysis and after adjustment by 
age and weight (not shown). The p-value was below the significance threshold after multiple 
test correction, which was estimated as 0.0085. Furthermore, the haplotype analysis 
confirmed an association with BMD, but it did not increase the statistical significance in 
comparison with the single locus analysis. Thus, the CTT haplotype at loci rs851056, 
rs12346012 and rs1230395 was significantly associated with spine BMD. The average BMD 
values were 0.851±0.147, 0.880±0.150 and 0.873±0.152 g/cm2, in women with 0, 1 and 2 CTT 
copies, respectively (p=0.031, table 4). 
Femoral neck.- There was no evidence for association of either SNPs or haplotypes with 
femoral neck BMD, although rs851056 alleles almost reached nominal statistical significance 
(p=0.06).  
Haplotypic blocks (defined according to the Gabriel method, see figure 2) were not 




The allele frequencies were similar in both cohorts (table 1). In the Valencia cohort we could 
not replicate the association of FRZB polymorphisms with either spine or femoral neck BMD. 
However, the rs851056 polymorphism of the SOST gene was associated with lumbar spine 
BMD (p=0.005).  
The combination of  the results of both cohorts confirmed a significant association of rs851056 
genotypes with BMD, with a weighted mean difference of 47 mg/cm2 (95% confidence interval 
24-70) between women with GG genotypes and those with other genotypes (GC or CC). As 
shown in table 5, the standardized mean weighted difference was 0.31 standard deviations 
(95% CI 0.16-0.46; p<0.0001).  
There was no evidence for association between SOST polymorphisms and femoral neck BMD 
in the single locus analysis (p=0.10 for the rs801056 polymorphism).   
FRZB and SOST expression 
FRZB and SOST transcripts were readily detected in bone samples by RT-qPCR. However, 
no significant association between rs4666865 alleles and FRZB expression was found in 
either bone samples or in the lymphoblastoid cell line database. Likewise. there were no 





The binding of Wnt ligands to their membrane receptors activate a number of intracellular 
signals, the best known of which constitute the so-called canonical pathway and involves an 
increase in ß-catenin, which induces the transcription of target genes 30;31. SFRP3, encoded 
by FRZB gene, is usually considered a Wnt antagonist. Nevertheless, it is still unclear whether 
it may promote Wnt actions on target cells under certain conditions 6. Targeting deletion of 
FRZB in mice appears to accelerate osteoarthritis 32, and FRZB polymorphisms, including 
rs7775,  have been associated with large joint osteoarthritis in humans 8;33. In the present 
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study we found an association of rs4666865 and neighbour SNPs, including rs7775, with BMD 
in postmenopausal women from the Cantabria cohort. However, the results could not be 
replicated in the Valencia cohort. Gao et al  recently studied four SNPs of the FRZB gene in 
Chinese families and explored their association with peak BMD. They found some suggestion 
for association of  rs4666865 alleles and lumbar spine BMD in the whole male offspring 
population (p=0.02), but no within-family evidence for association 34. Therefore, the possible 
association of FRZB allelic variants with either peak bone mass or bone loss in later life is still 
unclear. 
Sclerostin, the product of the SOST gene, inhibits Wnt signaling. Its role is emphasized by 
studies showing that the inhibition of sclerostin by means of targeted gene deletion or 
neutralizing antibodies increases bone mass 35;36. Osteocytes are the main source of 
sclerostin in the bone microenvironment, but little is known about the mechanisms regulating 
sclerostin synthesis 37;38. The  human SOST gene has two exons and spans about 5 kb on 
chromosome 17. A 52 kb deletion located in a noncoding region,  approximately 35 kb 
downstream of SOST gene (the Van Buchen region) may act as a gene transcription 
enhancer 9.   
In the present study we found a consistent association of the rs851056 polymorphism, located 
in the 5’ region of the gene, and lumbar spine BMD in two Spanish cohorts. These results are 
consistent with previous reports showing an association of several SNPs in this region with 
BMD 9;13;15;39. Although some negative results have also been reported 10, our data, showing 
an association in two different populations, add further support to the contention that allelic 
variants of the proximal region of the SOST gene are associated with BMD. Some 
investigators also found evidence for association of bone mass with the so-called Van Buchen 
region, located 35-87 downstream of the SOST gene. It was usually reported in studies with 
male individuals 9;39, suggesting that there might be some sex-specific influence.  However, in 
a large GWAS study including both men and women, three SNPs located between 23 kb and 
57 kb 3’ to the SOST gene were also associated with BMD 16.  Therefore, further studies are 
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needed to clarify whether SOST variants show sex-dependent associations with bone mass. 
We did not include Van Buchen region in our study. 
This rs851056 polymorphism is located around 1100 bp upstream of the SOST translation 
start site. Therefore, it can be speculated that its allelic variants influence gene transcription. 
In fact, the Fast SNP bioinformatics tool (http://fastsnp.ibms.sinica.edu.tw/pages 
/input_SNPListAnalysis.jsp) suggested that a putative binding site for c-Myc was lost in G 
alleles. We found no genotype-related differences in the abundance of RNA transcripts in a 
lymphoblastoid cell  expression database. However, the relevance of  those non-skeletal data 
is questionable. In studies of SOST expression in bone samples, we did not find differences 
across genotypes either. These data may be more relevant, but, given the relatively small 
number of samples studied, they should be interpreted with caution. It is also possible that 
rs801056 is linked to other polymorphisms which are the actual regulatory loci.  
This study has several limitations. First, it included only Caucasian women and therefore it is 
unclear if the results can be extrapolated to women from a different ethnicity or to men. 
Second, the size of the replication cohort was small. It is also worth to mention that women in 
the replication cohort were younger than in the discovery cohort. Therefore, the lack of 
replication of the association of FRZB polymorphisms may reflect a chance association in the 
discovery cohort, but it might also be the consequence of the limited statistical power for 
replication. Alternatively, if FRZB variants influence postmenopausal bone loss, rather than 
peak bone mass, genotypic differences in BMD might be more evident in women with longer 
duration of menopause. The study design was cross-sectional, clinic and volunteer-based, not 
population based. Therefore, although we tried to avoid potential biases,  some may remain. 
For instance, individuals with musculoskeletal complaints are likely to be over-represented. 
We excluded women with diseases or treatments known to have a powerful influence on bone 
mass, which may confound the genetic influence. We also excluded women with severe 
osteoarthritis, but we did not control for subtle skeletal degenerative changes. Therefore, 
since we found a stronger association of FRZB and SOST polymorphisms with spine BMD 
than with femoral BMD, it could be questioned whether the associations were actually the 
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consequence of a genetic influence on spine osteoarthritis, particularly for FRZB 
polymorphisms, which have been previously associated with large-joint osteoarthritis 8.  
Further studies with a prospective design are needed to clarify this issue, because 
osteoarthritis may spuriously influence BMD measurements, but, on the other hand, a true 
association between bone mass and osteoarthritis has also been suggested 40.  
In summary, this study confirms that polymorphisms in the 5’ region of SOST gene are 
associated with BMD in postmenopausal women. The molecular mechanisms involved remain 
to be elucidated. We also found an association of some  FRZB polymorphisms with BMD, but 
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Figure 1.  Association of  FRZB polymorphisms with lumbar spine and femoral neck BMD 
(Cantabria cohort). In the lower part, the haplotypic structure is shown. 
 
Figure 2.  Association of  SOST polymorphisms with lumbar spine and femoral neck BMD 
(Cantabria cohort). In the lower part, the haplotypic structure is shown. 
Table 1. Polymorphisms studied 
 













2 rs288316 FRZB 183403694 Intergenic A G 0.49  0.22  - 
2 rs17265803 FRZB 183404764 Intergenic C T 0.34  0.08  - 
2 rs4666865 FRZB 183406336 3’ G A 0.50 0.59 0.41 0.39 
2 rs7775 FRZB 183407829 Exon 6 
(Gly/Arg) 
G C 0.64 0.71 0.11 0.11 
2 rs6710705 FRZB 183408338 Intron 5 T C 0.14 0.13 0.08 0.08 
2 rs288324 FRZB 183409833 Intron 5 A G 0.54  0.48  - 
2 rs288326 FRZB 183411581 
Exon 4 
(Trp/Arg) A G 
0.04  
0.14  - 
2 rs7602601 FRZB 183431211 Intron 2 C T 0.52  0.15  - 
2 rs6433993 FRZB 183432193 Intron 1 G A 0.18  0.30  - 
2 rs7592998 FRZB 183432783 Intron 1 C T 0.17  0.06  - 
2 rs13026760 FRZB 183434958 Intron 1 C T 0.04  0.47  - 
2 rs12469777 FRZB 183440609 Intergenic C T 0.78  0.45  - 
17 rs17610444 SOST 39181383 Intergenic C T 0.04  0.04  - 
17 rs865429 SOST 39190741 Intron 1 C T 0.99  0.12  - 
17 rs17882143 SOST 39191608 Exon 1 
(Ile/Val) 
A G 0.11  0.03 - 
17 rs851054 SOST 39192149 5’ G A 0.73  0.38  - 
17 rs851056 SOST 39192708 5’ G C 0.96 0.24 0.38 0.38 
17 rs1234612 SOST 39196328 Intergenic C T 0.06 0.55 0.32 0.32 
17 rs1230395 SOST 39198463 Intergenic C T 0.03 0.99 0.08 0.07 
 
MAF: minor allele frequency 
Tables 1-5
Table 2. Characteristics of women included in the study (mean±SD) 
 
 Cantabria Valencia 
Age, yr 66±8 52±5  
BMI, kg/m2 27.9±4.3 26.5±14.3 
Years since menopause 16±10 4±4 
Spine BMD, T-score -1.7±1.3 -1.1±1.4 
Spine BMD, Z-score -0.1±1.4 -0.2 ±1.2 
Femur BMD, T-score -1.5±1.2 -0.9±1.0 
Femur BMD, Z-score 0.2±1.1 -0.1±1.0 
Table 3. Association of haplotypes of the FRZB  gene (rs466865-rs7775-rs6710705 










GCT 1.5 0.71 0.72 
ACT 6.2 0.72 0.41 
AGC 11.3 0.76 0.26 
GCC 39.3 0.0058 0.053 




Table 4. Association of haplotypes of the SOST gene (rs851056-rs1234612-








GCC 7.6 0.72 0.28 
CCT 24.3 0.26 0.18 
GTT 30.3 0.34 0.14 






Table 5. Lumbar spine BMD according to rs851056 (SOST) genotypes in both cohorts. 
Mean±SD [n] and standardized weighted difference (SWD, SD units and confidence 
interval). 
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